Brainstorm Cell Therapeutics Inc. (BCLI) Key Metrics
BCLI valuation today
Trailing 12 months · as of October 21, 2026- Market cap
- $8.5M
- Enterprise value
- $11.0M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 625.2
- Price / book
- 54.5
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.26
BCLI key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsBCLI valuation Price multiples at each fiscal year-end price.
Price / sales−48.9%
7.3
2025 · hover or tap a bar for each year
20162025
Free cash flow yield−61.4 pts
−136.8%
2025 · hover or tap a bar for each year
20162025
BCLI returns How much profit the business earns on the capital it uses.
Return on assets−1,194.2 pts
−809.3%
2025 · hover or tap a bar for each year
20162025
Asset turnover+96.4%
0.55
2025 · hover or tap a bar for each year
20162025
BCLI per-share figures Results divided by the shares outstanding at year-end.
Revenue per share−52.6%
$0.08
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$1.11
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
−$0.75
2025 · hover or tap a bar for each year
20162025
Book value per share
−$1.11
2025 · hover or tap a bar for each year
20162025
Shares outstanding+74.6%
9.3M
2025 · hover or tap a bar for each year
20162025
BCLI financial health Debt, liquidity and how easily interest is covered.
Net debt−$354,000
$179,000
2025 · hover or tap a bar for each year
20162025
Current ratio−35.0%
0.03
2025 · hover or tap a bar for each year
20162025
Debt / assets−26.0%
0.29
2025 · hover or tap a bar for each year
20162025
BCLI efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+14 days
39 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue0.0 pts
0.0%
2025 · hover or tap a bar for each year
20162025
BCLI valuation history
Fiscal year-endToday10-year median
BCLI returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
BCLI debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
BCLI cash returned to shareholders
DividendsBuybacksFree cash flow
BCLI price vs earnings per share
Share price at year-endEPS (right axis)
BCLI key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $5.1M | $12.1M | $15.5M | $60.2M | $145.5M | $153.4M | — | — | — | — |
| Enterprise value | $5.3M | $12.6M | $15.5M | $61.3M | $128.5M | $118.7M | — | — | — | — |
| P/E ratio | — | 1.0 | — | — | — | — | — | — | — | — |
| Price / sales | 7.3 | 14.2 | — | — | — | — | — | — | — | — |
| Price / book | — | — | — | — | 7.5 | 4.3 | — | — | — | — |
| EV / sales | 7.5 | 14.8 | — | — | — | — | — | — | — | — |
| Earnings yield | −202.2% | 96.4% | −110.6% | −39.5% | −16.8% | −20.7% | — | — | — | — |
| Free cash flow yield | −136.8% | −75.4% | −131.7% | −32.2% | −18.3% | −23.2% | — | — | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | — | 0.0% | 0.1% | — | — | — | — |
| Share price at fiscal year-end | $0.55 | $2.27 | $4.05 | $24.60 | $60.00 | $67.95 | $64.20 | $53.25 | $58.80 | $38.10 |
| Per share | ||||||||||
| Revenue per share | $0.08 | $0.16 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — |
| Earnings per share | −$1.11 | $2.19 | −$4.48 | −$9.71 | −$10.09 | −$14.09 | — | — | — | — |
| Operating cash flow per share | −$0.75 | −$1.71 | −$5.33 | −$7.90 | −$10.83 | −$15.59 | — | — | — | — |
| Free cash flow per share | −$0.75 | −$1.71 | −$5.33 | −$7.91 | −$10.97 | −$15.76 | — | — | — | — |
| Cash per share | $0.00 | $0.04 | $0.34 | $1.22 | $9.11 | $18.58 | — | — | — | — |
| Book value per share | −$1.11 | −$1.46 | −$1.27 | −$1.23 | $7.98 | $15.71 | — | — | — | — |
| Tangible book value per share | −$1.11 | −$1.46 | −$1.27 | −$1.23 | $7.97 | $15.70 | — | — | — | — |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.01 | $0.14 | $0.17 | — | — | — | — |
| Debt per share | $0.02 | $0.14 | $0.33 | $1.67 | $2.09 | $3.20 | — | — | — | — |
| Shares outstanding | 9.3M | 5.3M | 3.8M | 2.4M | 2.4M | 2.3M | — | — | — | — |
| Change in shares outstanding | +74.6% | +38.3% | +57.0% | +0.8% | +7.4% | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | — | — | — | −89.2% | −273.7% | — | −256.0% | −62.8% | −41.5% |
| Return on assets (ROA) | −809.3% | 384.9% | −271.6% | −125.8% | −60.7% | −110.1% | −261.8% | −123.2% | −44.6% | −35.8% |
| Return on tangible assets | — | 634.4% | −408.8% | −280.8% | −83.6% | −62.1% | −356.6% | −124.2% | −43.4% | −46.3% |
| Free cash flow margin | −992.2% | — | — | — | — | — | — | — | — | — |
| Income quality (OCF / net income) | — | −0.78 | — | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $208,000 | $720,000 | $1.3M | $4.1M | $5.1M | $7.2M | $2.4M | — | $0 | $0 |
| Cash & short-term investments | $29,000 | $187,000 | $1.3M | $3.0M | $22.1M | $41.9M | $569,000 | $7.1M | $7.8M | $10.0M |
| Net debt | $179,000 | $533,000 | −$25,000 | $1.1M | −$17.0M | −$34.7M | $1.8M | −$7.1M | −$7.8M | −$10.0M |
| Debt / equity | — | — | — | — | 0.26 | 0.20 | — | — | 0.00 | 0.00 |
| Debt / assets | 0.29 | 0.39 | 0.30 | 0.48 | 0.17 | 0.14 | 0.36 | — | 0.00 | 0.00 |
| Current ratio | 0.03 | 0.04 | 0.24 | 0.35 | 3.69 | 3.85 | 0.19 | 1.65 | 1.74 | 12.09 |
| Quick ratio | 0.03 | 0.04 | 0.25 | 0.35 | 3.69 | 3.85 | 0.19 | 1.65 | 1.74 | 12.09 |
| Interest coverage | — | -151.9 | — | -45.5 | -299.3 | -249.5 | -91.3 | -122.3 | -106.4 | -50.3 |
| Working capital | −$10.7M | −$8.6M | −$5.9M | −$5.7M | $17.0M | $32.0M | −$14.3M | $4.1M | $4.1M | $9.6M |
| Invested capital | −$10.1M | −$7.2M | −$4.9M | −$1.9M | $2.3M | $745,000 | −$10.4M | −$2.0M | −$1.9M | −$88,000 |
| Tangible asset value | −$10.3M | −$7.8M | −$4.9M | −$3.0M | $19.3M | $35.4M | −$12.2M | $5.0M | $5.9M | $9.9M |
| Net current asset value | −$10.7M | −$9.2M | −$7.2M | −$8.4M | $13.3M | $27.4M | −$15.4M | $4.1M | $4.1M | $9.6M |
| Graham net-net per share | −$1.18 | −$1.76 | −$2.02 | −$3.44 | $5.04 | $11.68 | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $0 | $0 |
| Share buybacks (net) | — | — | — | — | $0 | $116,000 | $0 | $0 | $0 | $0 |
| Capex / revenue | 0.0% | 0.0% | — | — | — | — | — | — | — | — |
| Capex / depreciation | 0.00 | 0.00 | 0.07 | 0.10 | 1.27 | 1.73 | 2.88 | 3.35 | 2.12 | 1.34 |
| Stock-based compensation / revenue | 216.2% | 88.3% | — | — | — | — | — | — | — | — |
| R&D / revenue | 593.9% | 519.6% | — | — | — | — | — | — | — | — |
| SG&A / revenue | 821.9% | 829.4% | — | — | — | — | — | — | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | 38.7 | 24.5 | — | — | — | — | — | — | — | — |
| Days of inventory on hand | — | — | -70.2 | — | — | — | — | — | — | — |
| Days payables outstanding | — | 8,390.4 | 7,698.1 | 6,354.8 | 6,399.4 | 16,745.0 | 9,586.2 | 11,031.3 | 6,039.7 | 5,129.0 |
| Cash conversion cycle (days) | — | -8,365.9 | — | — | — | — | — | — | — | — |
| Receivables turnover | 9.44 | 14.89 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables turnover | — | 0.04 | 0.05 | 0.06 | 0.06 | 0.02 | 0.04 | 0.03 | 0.06 | 0.07 |
| Asset turnover | 0.55 | 0.28 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $74,500 | $57,000 | $71,000 | $88,500 | $195,000 | $1.3M | $2.2M | $1.3M | $489,000 | $532,500 |
| Average payables | $6.6M | $5.5M | $5.6M | $5.0M | $4.6M | $10.0M | $9.6M | $3.3M | $1.4M | $1.1M |
| Average inventory | — | — | −$51,000 | — | — | — | — | — | $0 | $0 |
| Intangibles / total assets | 0.0% | 0.0% | 0.1% | 0.0% | 0.1% | 0.1% | 0.2% | 0.0% | 0.0% | 0.0% |
Computed from BCLI's annual financial statements (latest annual report filed March 31, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
BCLI valuation and financial ratios
It ended the year with $0.2 million of debt and $0.0 million in cash and short-term investments, net debt of $0.2 million.
See the BCLI income statement, the BCLI chart for price history, or the BCLI stock overview for the latest quote and news.
BCLI key metrics FAQ
How much debt does Brainstorm Cell Therapeutics have?
Brainstorm Cell Therapeutics had total debt of $0.2 million at the end of fiscal 2025.
What is Brainstorm Cell Therapeutics's free cash flow yield?
Brainstorm Cell Therapeutics generated -$7.0 million of free cash flow in fiscal 2025, a free cash flow yield of −136.8% on its market value at year-end ($5.1 million).
What is Brainstorm Cell Therapeutics's current ratio?
Brainstorm Cell Therapeutics's current ratio was 0.03 at the end of fiscal 2025: current assets were 0.03 times current liabilities.